A deep dive into Shilpa Medicare Limited (SHILPAMED) — examining the financials, valuation picture, and who owns the stock.
Shilpa Medicare Revenue Trend
Shilpa Medicare Limited managed to grow its top line 11.7% in FY2025, with revenue hitting ₹1,286 Cr.
Shilpa Medicare Limited's revenue compounded at 7.7% over 10 years — not a breakout compounder, but steady enough to suggest a stable business.
At ₹1,286 Cr in annual revenue, Shilpa Medicare Limited is one of the mid-sized players in the pharmaceuticals space.
| Year | Revenue | YoY % |
|---|---|---|
| FY2025 | ₹1,286 Cr | +11.7% |
| FY2024 | ₹1,152 Cr | +9.7% |
| FY2023 | ₹1,050 Cr | -9.5% |
| FY2022 | ₹1,160 Cr | +24.5% |
| FY2021 | ₹931 Cr | — |
View Shilpa Medicare Limited's full 10-year revenue trend with CAGR analysis →
Shilpa Medicare Profitability
Shilpa Medicare Limited delivered net profit of ₹78.3 Cr in FY2025, a solid 145.6% jump from ₹31.9 Cr in FY2024.
Net profit margin improved to 6.1% in FY2025 from 2.8% in FY2024, indicating better cost control.
The diluted EPS figure moved up to ₹4.02 in FY2025, against ₹1.84 posted in FY2024.
Is Shilpa Medicare Undervalued
Per the P/E Ratio model, Shilpa Medicare Limited has an estimated intrinsic value of ₹321 (37.7% downside).
Shilpa Medicare Limited shares are currently trading at ₹515.40.
Craytheon also calculates intrinsic value using the EPS Growth model. The full breakdown with assumptions is available in the detailed analysis.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹321 | 37.7% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
See all valuation models for Shilpa Medicare Limited with detailed assumptions →
Shilpa Medicare Shareholding Pattern
Promoter stake dipped to 40.1% from 44.2% over 4 quarters — something to monitor.
FII ownership stands at 11.1%, down from the 11.2% recorded a year ago.
Domestic investors held 8.6% of the company as of March 2026, up year-over-year from 7.5%.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 40.1% | 11.1% | 8.6% | 40.2% |
| Dec 2025 | 40.1% | 11.0% | 8.3% | 40.6% |
| Sep 2025 | 44.2% | 10.9% | 7.7% | 37.2% |
| Jun 2025 | 44.2% | 11.2% | 7.5% | 37.1% |
Track quarterly shareholding changes for Shilpa Medicare Limited →
Shilpa Medicare Balance Sheet
Proportional view as of 3 Jun 2026. Hover blocks for details.
Assets
Liabilities & Equity
Total assets stood at ₹33.11B at the end of FY2025, up 7.0% from ₹30.93B a year earlier.
Property, Plant & Equipment is the largest block at 49.8%, followed by Other Assets at 18.3% and Receivables at 13.3%.
Equity makes up 71.4% of liabilities and equity, with debt at 17.8% and operating liabilities at 10.9%. Over the year, debt is down 37.3% and equity is up 31.3%.
Balance sheet composition — FY 2025
| Category | Value |
|---|---|
| Cash & ST Investments | 259.68M |
| Receivables | 4.41B |
| Inventories | 3.48B |
| Property, Plant & Equipment | 16.49B |
| Investments | 345.39M |
| Intangibles & Goodwill | 2.05B |
| Other Assets | 6.07B |
| Category | Value |
|---|---|
| Equity | 23.64B |
| Short-term Debt | 3.55B |
| Long-term Debt | 2.33B |
| Trade Payables | 953.82M |
| Other Liabilities | 2.64B |
Shilpa Medicare at a Glance
In summary, Shilpa Medicare Limited (SHILPAMED) presents the following picture for fundamental analysts.
Revenue of ₹1,286 Cr in FY2025, up 11.7% year-over-year.
Long-term revenue has been compounding at 7.7% annually over 10 years.
The company is profitable, with a net margin of 6.1% and net income of ₹78.3 Cr.
The P/E Ratio model implies 37.7% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
Want to dig deeper? Craytheon's platform provides 10 years of financial data, three valuation models, and insider trading activity for Shilpa Medicare Limited.